Chlamydia Infection Among Adolescent Long-Acting Reversible Contraceptive (LARC) and Shorter Acting Hormonal Contraceptive Users Receiving Services at New York City School-Based Health Centers.
One concern regarding long acting reversible contraception (LARC) use among female adolescents is the potential for sexually transmitted infection (STI) acquisition. Few studies investigate chlamydia infection among adolescent LARC users compared to other hormonal contraceptive method (non-LARC) users. We hypothesized that incident chlamydia infection would be similar in these two groups and that it would not be associated with adolescent LARC use. Secondary data analysis of electronic health records of adolescents initiating LARC (n=152) and non-LARC methods (n=297) at six New York City (NYC) School-Based Health Centers (SBHCs) between March 2015 and March 2017. Demographics, sexual risk factors and occurrence of chlamydia infection over a period of 1 year were compared in the two groups using χ2 tests and t tests. Multivariable logistic regression was used to test the association between LARC use and chlamydia infection adjusting for relevant covariates. Among adolescent patients tested the year following method initiation, 48 (11.4%) had at least one positive chlamydia test. The proportions of LARC users and non-LARC users with chlamydia infection were not statistically significantly different (10.9 % vs. 11.6%, p: 0.82). Multivariable analysis demonstrated that LARC use was not associated with greater chlamydia risk (aOR: 0.84, 95% CI 0.41-1.43). Adolescent LARC users did not have significantly higher chlamydia infection occurrence compared to non-LARC users the year following method initiation. Concern for chlamydial infection should prompt recommending condom use but should not be a barrier to recommending adolescent LARC use.